Annexon Inc. (ANNX) is threading together a trio of late-stage programs that could reshape treatment options across neurology, ophthalmology, and autoimmunity. With global filings, pivotal data, and mechanistic innovation converging through 2026, the company is building momentum around a single molecular target, C1q, and translating it into three distinct therapeutic strategies.
Tanruprubart for Guillain-Barré Syndrome: Regulatory Engagement Underway
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.